We are Apellis Pharmaceuticals

Who We Are More about us

Apellis Pharmaceuticals is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
Our approach is centered on the inhibition of the complement system, which is a cascade of interacting proteins and is an integral component of the immune system.
We are developing our lead product candidates to treat paroxysmal nocturnal hemoglobinuria, or PNH, geographic atrophy, or GA, intermediate age-related macular degeneration, or intermediate AMD, and chronic obstructive pulmonary disease, or COPD.

Facts on Complement-Mediated Diseases

$583,000: Approximate cost per year of treatment with Soliris, the standard of care in PNH

We estimate there are approximately 4,700 patients with PNH in the United States.

If not treated with complement inhibition, PNH results in the death of about 35% of the patients within five years of diagnosis.

Formation of blood clots is the main cause of death for people afflicted with PNH.
AMD is a disease of aging that is usually observed in people over the age of 50.

It is estimated that approximately 15 million patients in the United States suffer from some form of AMD.

AMD can be classified as either early or intermediate AMD, wet AMD, and geographic atrophy.

Early and intermediate AMD are characterized by the presence of deposits (drusen) in the retina but does not cause serious vision loss. These stages precede wet AMD and geographic atrophy.

Wet AMD is characterized by the growth of blood vessels into the retina that rapidly leads to blindness if not treated.

Geographic atrophy is a form of dry AMD characterized slow progressive retinal death which starts in periphery. Patients become blind when central vision is affected.
It is estimated that 65 million patients worldwide suffer from moderate to severe COPD, including 15 million in the USA.

There are 4 stages of the disease ranging from mild (GOLD 1) to very severe (GOLD 4).

COPD represents a significant unmet need.

Find Us

Call Us
(502) 241-4114
6400 Westwind Way,
Suite A
Crestwood, KY 40014, USA
info@apellis.com investors@apellis.com clinicaltrials@apellis.com